Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals reports record Q4 revenue of $247.1 million, up 29.6%

Positive Impact 3 of 5 earnings Written later

ANI Pharmaceuticals reported record fourth-quarter and full-year 2025 results, with Q4 net revenue of $247.1 million and GAAP net income available to common shareholders of $27.5 million, compared with a loss in the prior-year quarter. The company reaffirmed its full-year 2026 guidance, including total net revenue of $1,055 million to $1,115 million, which matters to shareholders as a reaffirmation rather than a change in outlook.

Key points

  • Q4 2025 net revenue was $247.1 million, up 29.6%; Cortrophin Gel rose 87.6% to $111.4 million, while Brands fell 37.9% to $12.3 million
  • Q4 GAAP diluted EPS was $1.18 versus a loss of $0.55 a year earlier; adjusted non-GAAP diluted EPS was $2.33 versus $1.63
  • Full-year 2025 net revenue was $883.4 million, up 43.8%, with GAAP net income available to common shareholders of $77.2 million
  • 2026 guidance reaffirmed: total net revenue $1,055 million to $1,115 million and adjusted non-GAAP diluted EPS $8.83 to $9.34

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECFeb 27, 2026, 6:57 AM ET
Accession number0001023024-26-000013

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.